Literature DB >> 7944702

Comparison of two strategies for myocardial management during coronary artery operations.

J R Anderson1, M Hossein-Nia, P Kallis, M Pye, D W Holt, A J Murday, T Treasure.   

Abstract

Despite the current trend for using blood cardioplegia, ventricular fibrillation with intermittent ischemia is still used as a strategy to manage the myocardium with impressive results. These two methods of myocardial management were compared in 40 patients undergoing elective coronary artery operations using creatine kinase MB isoforms and troponin T assays. Each patient was randomized to have either cold blood cardioplegia (n = 20) or ventricular fibrillation with intermittent ischemia (n = 20) for myocardial management during the construction of distal anastomoses. Until recently, the comparison of different methods of myocardial management has been hindered by the lack of a specific and sensitive marker of myocardial damage. Analysis of creatine kinase MB isoforms (MB2, cardiac tissue form; MB1, plasma-modified form) and cardiac-specific troponin T (a structural protein) has been shown to improve the sensitivity for the detection of myocardial damage. There were no significant differences between the two groups in age, sex ratio, extent of disease, or left ventricular function. Blood samples for analysis were collected before cross-clamp application and at time intervals up to 48 hours after. Median peak creatine kinase MB2 activity was found to be significantly higher in the blood cardioplegia group compared with ventricular fibrillation (26.5 U/L versus 19.5 U/L, respectively, p = 0.04). Although median peak troponin T concentration was higher in the blood cardioplegia group, the difference failed to reach significance (2.2 ng/mL versus 1.6 ng/mL, p = 0.15).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7944702     DOI: 10.1016/0003-4975(94)90745-5

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

1.  Intraoperative cardiac troponin T release and lactate metabolism during coronary artery surgery: comparison of beating heart with conventional coronary artery surgery with cardiopulmonary bypass.

Authors:  T W Koh; G S Carr-White; A C DeSouza; F D Ferdinand; J Hooper; M Kemp; D G Gibson; J R Pepper
Journal:  Heart       Date:  1999-05       Impact factor: 5.994

2.  Ischaemic preconditioning reduces troponin T release in patients undergoing coronary artery bypass surgery.

Authors:  D P Jenkins; W B Pugsley; A M Alkhulaifi; M Kemp; J Hooper; D M Yellon
Journal:  Heart       Date:  1997-04       Impact factor: 5.994

3.  Metabolic derangement and cardiac injury early after reperfusion following intermittent cross-clamp fibrillation in patients undergoing coronary artery bypass graft surgery using conventional or miniaturized cardiopulmonary bypass.

Authors:  Bao A V Nguyen; M-Saadeh Suleiman; Jonathan R Anderson; Paul C Evans; Francesca Fiorentino; Barnaby C Reeves; Gianni D Angelini
Journal:  Mol Cell Biochem       Date:  2014-06-17       Impact factor: 3.396

4.  Intraoperative release of troponin T in coronary venous and arterial blood and its relation to recovery of left ventricular function and oxidative metabolism following coronary artery surgery.

Authors:  T W Koh; J Hooper; M Kemp; F D Ferdinand; D G Gibson; J R Pepper
Journal:  Heart       Date:  1998-10       Impact factor: 5.994

5.  Coronary surgery with non-cardioplegic methods in patients with advanced left ventricular dysfunction: immediate and long term results.

Authors:  P E Antunes; J M Ferrão de Oliveira; M J Antunes
Journal:  Heart       Date:  2003-04       Impact factor: 5.994

6.  Coronary bypass grafting using crossclamp fibrillation does not result in reliable reperfusion of the myocardium when the crossclamp is intermittently released: a prospective cohort study.

Authors:  Joel Dunning; Steven Hunter; Simon W H Kendall; John Wallis; W Andrew Owens
Journal:  J Cardiothorac Surg       Date:  2006-11-21       Impact factor: 1.637

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.